	US 12,410,445 B2
	Vector system for expressing regulatory RNA
Tyler Lahusen, Rockville, MD (US); Lingzhi Xiao, Rockville, MD (US); and Charles David Pauza, Rockville, MD (US)
Assigned to American Gene Technologies International Inc., Rockville, MD (US)
Filed by American Gene Technologies International Inc., Rockville, MD (US)
Filed on Mar. 22, 2022, as Appl. No. 17/701,488.
Application 17/701,488 is a continuation of application No. 17/289,653, granted, now 11,352,646, previously published as PCT/US2019/059828, filed on Nov. 5, 2019.
Claims priority of provisional application 62/755,985, filed on Nov. 5, 2018.
Prior Publication US 2022/0372513 A1, Nov. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); C12N 15/113 (2010.01)

CPC C12N 15/86 (2013.01) [C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2740/15023 (2013.01); C12N 2740/15043 (2013.01)]

17 Claims

1. A modified mesenchymal stem cell comprising a mesenchymal stem cell infected with a lentiviral particle, wherein the lentiviral particle comprises:

an envelope protein capable of infecting the mesenchymal stem cell; and

a first nucleotide sequence encoding a small RNA capable of binding a non-coding region of a host copy of KIF11, wherein the first nucleotide sequence encoding a small RNA is present in the modified mesenchymal stem cell at between about 1 and about 10 copies per cell.